PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis
May 23, 2022 at 8:30 AM EDT
Conference Call Dial-In & Webcast Information:
| Date: | |
| Time: | |
| +1 877-870-9135 | |
| +972 1809 213-985 | |
| International: | +44 (0) 2071 928338 |
| Conference ID: | 4857305 |